Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study.
Bianchi A, De Rimini ML, Sciuto R, Annovazzi A, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Scarlattei M, Baldari G, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, Evangelista L. Bianchi A, et al. Among authors: caroli p. Cancer Biother Radiopharm. 2023 May;38(4):256-267. doi: 10.1089/cbr.2022.0092. Epub 2023 Apr 25. Cancer Biother Radiopharm. 2023. PMID: 37098169
ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors.
Evangelista L, Bianchi A, Annovazzi A, Sciuto R, Di Traglia S, Bauckneht M, Lanfranchi F, Morbelli S, Nappi AG, Ferrari C, Rubini G, Panareo S, Urso L, Bartolomei M, D'Arienzo D, Valente T, Rossetti V, Caroli P, Matteucci F, Aricò D, Bombaci M, Caponnetto D, Bertagna F, Albano D, Dondi F, Gusella S, Spimpolo A, Carriere C, Balma M, Buschiazzo A, Gallicchio R, Storto G, Ruffini L, Cervati V, Ledda RE, Cervino AR, Cuppari L, Burei M, Trifirò G, Brugola E, Zanini CA, Alessi A, Fuoco V, Seregni E, Deandreis D, Liberini V, Moreci AM, Ialuna S, Pulizzi S, De Rimini ML. Evangelista L, et al. Among authors: caroli p. Cancers (Basel). 2023 Jan 31;15(3):878. doi: 10.3390/cancers15030878. Cancers (Basel). 2023. PMID: 36765835 Free PMC article.
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective Study.
Mattoni S, Farolfi A, Formaggio F, Bruno G, Caroli P, Cerci JJ, Eiber M, Fendler WP, Golfieri R, Herrmann K, Matteucci F, Mosconi C, Paolani G, Santoro M, Strigari L, Nanni C, Castellucci P, Fanti S. Mattoni S, et al. Among authors: caroli p. Cancers (Basel). 2022 Nov 18;14(22):5680. doi: 10.3390/cancers14225680. Cancers (Basel). 2022. PMID: 36428771 Free PMC article.
Theragnostic in neuroendocrine tumors.
Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Marini I, et al. Among authors: caroli p. Q J Nucl Med Mol Imaging. 2021 Dec;65(4):342-352. doi: 10.23736/S1824-4785.21.03426-9. Epub 2021 Dec 9. Q J Nucl Med Mol Imaging. 2021. PMID: 34881852
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome.
Conteduca V, Scarpi E, Caroli P, Lolli C, Gurioli G, Brighi N, Poti G, Farolfi A, Altavilla A, Schepisi G, Matteucci F, Paganelli G, De Giorgi U. Conteduca V, et al. Among authors: caroli p. Mol Oncol. 2022 Jan;16(2):538-548. doi: 10.1002/1878-0261.13120. Epub 2021 Nov 9. Mol Oncol. 2022. PMID: 34657387 Free PMC article.
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging.
Conteduca V, Poti G, Caroli P, Russi S, Brighi N, Lolli C, Schepisi G, Romeo A, Matteucci F, Paganelli G, Marchetti P, De Giorgi U. Conteduca V, et al. Among authors: caroli p. Ther Adv Med Oncol. 2021 Feb 24;13:1758835920987654. doi: 10.1177/1758835920987654. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33708265 Free PMC article. Review.
Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.
Nicolini S, Bodei L, Bongiovanni A, Sansovini M, Grassi I, Ibrahim T, Monti M, Caroli P, Sarnelli A, Diano D, Di Iorio V, Grana CM, Cittanti C, Pieri F, Severi S, Paganelli G. Nicolini S, et al. Among authors: caroli p. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3260-3267. doi: 10.1007/s00259-021-05236-z. Epub 2021 Feb 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33604690 Free PMC article. Clinical Trial.
39 results